Open access · OA
via OpenAlex
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Olivia Finney, Hannah Brakke, Stephanie Rawlings-Rhea, Roxana Hicks, Danielle Doolittle, M. I. Esteban López, Ben Futrell, Rimas J. Orentas, Daniel Li, Rebecca Gardner, Michael C. Jensen
Journal of Clinical Investigation · 2019 · ▲ 347 citations
Abstract
BACKGROUND: Chimeric antigen receptor (CAR) T cells can induce remission in highly refractory leukemia and lymphoma subjects, yet the parameters for achieving sustained relapse-free survival are not fully delineated. METHODS: We analyzed 43 pediatric and young adult subjects participating in a Phase I trial of defined composition CD19CAR T cells (NCT02028455). CAR T cell phenotype, function and expansion, as well as starting material T cell repertoire, were analyzed in relation to therapeutic outcome (defined as achieving complete remission within 63 days) and duration of leukemia free survival and B cell aplasia. RESULTS: These analyses reveal that initial therapeutic failures (n = 5) were associated with attenuated CAR T cell expansion and/or rapid attrition of functional CAR effector cells following adoptive transfer. The CAR T products were similar in phenotype and function when compared to products resulting in sustained remissions. However, the initial apheresed peripheral blood T cells could be distinguished by an increased frequency of LAG-3+/TNF-αlow CD8 T cells and, following adoptive transfer, the rapid expression of exhaustion markers. For the 38 subjects who achieved an initial sustained MRD-neg remission, remission durability correlated with therapeutic products having increased frequencies of TNF-α-secreting CAR CD8+ T cells, and was dependent on a sufficiently high CD19+ antigen load at time of infusion to trigger CAR T cell proliferation. CONCLUSION: These parameters have the potential to prospectively identify patients at risk for therapeutic failure and support the development of approaches to boost CAR T cell activation and proliferation in patients with low levels of CD19 antigen. TRIAL REGISTRATION: ClinicalTrials.gov NCT02028455. FUNDING: Partial funding for this study was provided by Stand Up to Cancer & St. Baldrick's Pediatric Dream Team Translational Research Grant (SU2C-AACR-DT1113), RO1 CA136551-05, Alex Lemonade Stand Phase I/II Infrastructure Grant, Conquer Cancer Foundation Career Development Award, Washington State Life Sciences Discovery Fund, Ben Towne Foundation, William Lawrence & Blanche Hughes Foundation, and Juno Therapeutics, Inc., a Celgene Company.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1172/jci125423
- Canonical
- link ↗
- Fetched
- 2026-06-07 MST
Cite this
APA
Finney, O., Brakke, H., Rawlings-Rhea, S., Hicks, R., Doolittle, D., López, M.I.E., Futrell, B., Orentas, R.J., Li, D., Gardner, R., & Jensen, M.C. (2019). CD19 CAR T cell product and disease attributes predict leukemia remission durability. <em>Journal of Clinical Investigation</em>. https://doi.org/10.1172/jci125423
Vancouver
Finney O, Brakke H, Rawlings-Rhea S, Hicks R, Doolittle D, López MIE, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. Journal of Clinical Investigation. 2019. doi:10.1172/jci125423.
BibTeX
@article{olivia2019CDCART,
title = {CD19 CAR T cell product and disease attributes predict leukemia remission durability},
author = {Olivia Finney and Hannah Brakke and Stephanie Rawlings-Rhea and Roxana Hicks and Danielle Doolittle and M. I. Esteban López and Ben Futrell and Rimas J. Orentas and Daniel Li and Rebecca Gardner and Michael C. Jensen},
journal = {Journal of Clinical Investigation},
year = {2019},
doi = {10.1172/jci125423},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Stem Cells 2005
Citation only
Characterization of the Optimal Culture Conditions for Clinical Scale Production of Human Mesenchymal Stem Cells
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 2019
Open access · US-GOV
Up-front Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia Aged 65-75
Molecular Oncology 2014
Open access · OA
CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas
Nature Communications 2021
Open access · CC-BY
DMRT1-mediated reprogramming drives development of cancer resembling human germ cell tumors with features of totipotency
Anticancer Research 2024
Open access · CC-BY
Genotoxic and Cytotoxic Activity of Fisetin on Glioblastoma Cells
Institut Paoli-Calmettes 2006
Open access · US-GOV